Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Total Current Liabilities (2020 - 2025)

Arcutis Biotherapeutics (ARQT) has 6 years of Total Current Liabilities data on record, last reported at $129.8 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 60.27% year-over-year to $129.8 million; the TTM value through Dec 2025 reached $129.8 million, up 60.27%, while the annual FY2025 figure was $129.8 million, 60.27% up from the prior year.
  • Total Current Liabilities reached $129.8 million in Q4 2025 per ARQT's latest filing, up from $91.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $172.4 million in Q3 2024 and bottomed at $19.1 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $66.6 million, with a median of $46.7 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: grew 13.45% in 2022, then skyrocketed 73.59% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $33.3 million in 2021, then increased by 13.45% to $37.8 million in 2022, then rose by 23.44% to $46.7 million in 2023, then surged by 73.59% to $81.0 million in 2024, then surged by 60.27% to $129.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $129.8 million in Q4 2025, $91.1 million in Q1 2025, and $81.0 million in Q4 2024.